JP2017530154A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530154A5 JP2017530154A5 JP2017517705A JP2017517705A JP2017530154A5 JP 2017530154 A5 JP2017530154 A5 JP 2017530154A5 JP 2017517705 A JP2017517705 A JP 2017517705A JP 2017517705 A JP2017517705 A JP 2017517705A JP 2017530154 A5 JP2017530154 A5 JP 2017530154A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- ring
- hydroxy
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 226
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 104
- 125000005842 heteroatom Chemical group 0.000 claims description 88
- 229910052760 oxygen Inorganic materials 0.000 claims description 88
- 229910052717 sulfur Inorganic materials 0.000 claims description 88
- 229910052739 hydrogen Inorganic materials 0.000 claims description 77
- 229910052799 carbon Inorganic materials 0.000 claims description 72
- 125000000623 heterocyclic group Chemical group 0.000 claims description 61
- 125000004432 carbon atom Chemical group C* 0.000 claims description 55
- 239000001257 hydrogen Substances 0.000 claims description 55
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 55
- 125000005843 halogen group Chemical group 0.000 claims description 49
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims description 46
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims description 46
- -1 haloC 1 -C 3 alkyl Chemical group 0.000 claims description 44
- 150000002431 hydrogen Chemical group 0.000 claims description 38
- 229910052736 halogen Inorganic materials 0.000 claims description 33
- 150000002367 halogens Chemical group 0.000 claims description 33
- 125000004043 oxo group Chemical group O=* 0.000 claims description 33
- 229920006395 saturated elastomer Polymers 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 32
- 102100020683 Beta-klotho Human genes 0.000 claims description 31
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 claims description 31
- 101001139095 Homo sapiens Beta-klotho Proteins 0.000 claims description 31
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 15
- 150000001204 N-oxides Chemical class 0.000 claims description 11
- 125000002619 bicyclic group Chemical group 0.000 claims description 11
- 125000004122 cyclic group Chemical group 0.000 claims description 11
- 125000001475 halogen functional group Chemical group 0.000 claims description 11
- 125000003566 oxetanyl group Chemical group 0.000 claims description 11
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims description 11
- 125000006413 ring segment Chemical group 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 239000012472 biological sample Substances 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000036210 malignancy Effects 0.000 claims description 9
- WWXYIWRCALKTTD-UHFFFAOYSA-N 6-[[acetyl(methyl)amino]methyl]-N-(5-cyanopyridin-2-yl)-7-formyl-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound CN(Cc1cc2CCCN(C(=O)Nc3ccc(cn3)C#N)c2nc1C=O)C(C)=O WWXYIWRCALKTTD-UHFFFAOYSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- DNJLKERWZGKXBF-UHFFFAOYSA-N N-(5-cyanopyridin-2-yl)-7-formyl-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound O=Cc1ccc2CCCN(C(=O)Nc3ccc(cn3)C#N)c2n1 DNJLKERWZGKXBF-UHFFFAOYSA-N 0.000 claims description 2
- HXNZAVZZAPTZBP-UHFFFAOYSA-N N-(5-cyanopyridin-2-yl)-7-formyl-6-(hydroxymethyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound OCc1cc2CCCN(C(=O)Nc3ccc(cn3)C#N)c2nc1C=O HXNZAVZZAPTZBP-UHFFFAOYSA-N 0.000 claims description 2
- GBJIYJAVKBUOHN-UHFFFAOYSA-N N-[5-cyano-4-(2-methoxyethoxy)pyridin-2-yl]-6-(difluoromethyl)-7-formyl-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound COCCOc1cc(NC(=O)N2CCCc3cc(C(F)F)c(C=O)nc23)ncc1C#N GBJIYJAVKBUOHN-UHFFFAOYSA-N 0.000 claims description 2
- RVTLBVODLXUYNU-UHFFFAOYSA-N N-[5-cyano-4-(2-methoxyethoxy)pyridin-2-yl]-7-formyl-6-(hydroxymethyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound COCCOc1cc(NC(=O)N2CCCc3cc(CO)c(C=O)nc23)ncc1C#N RVTLBVODLXUYNU-UHFFFAOYSA-N 0.000 claims description 2
- LGFNXKJQQVMYQI-UHFFFAOYSA-N N-[5-cyano-4-(2-methoxyethoxy)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound COCCOc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N LGFNXKJQQVMYQI-UHFFFAOYSA-N 0.000 claims description 2
- SYRAVIOIIKVUFT-UHFFFAOYSA-N N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-(hydroxymethyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound COCCNc1cc(NC(=O)N2CCCc3cc(CO)c(C=O)nc23)ncc1C#N SYRAVIOIIKVUFT-UHFFFAOYSA-N 0.000 claims description 2
- BHKDKKZMPODMIQ-UHFFFAOYSA-N N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N BHKDKKZMPODMIQ-UHFFFAOYSA-N 0.000 claims description 2
- JDSIDNMVOWOKBD-MRXNPFEDSA-N N-[5-cyano-4-[(3R)-oxolan-3-yl]oxypyridin-2-yl]-7-formyl-6-(hydroxymethyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound C(#N)C=1C(=CC(=NC1)NC(=O)N1CCCC2=CC(=C(N=C12)C=O)CO)O[C@H]1COCC1 JDSIDNMVOWOKBD-MRXNPFEDSA-N 0.000 claims description 2
- JDSIDNMVOWOKBD-INIZCTEOSA-N N-[5-cyano-4-[(3S)-oxolan-3-yl]oxypyridin-2-yl]-7-formyl-6-(hydroxymethyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound C(#N)C=1C(=CC(=NC1)NC(=O)N1CCCC2=CC(=C(N=C12)C=O)CO)O[C@@H]1COCC1 JDSIDNMVOWOKBD-INIZCTEOSA-N 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 206010073069 Hepatic cancer Diseases 0.000 claims 1
- 229940001468 citrate Drugs 0.000 claims 1
- 150000001860 citric acid derivatives Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 description 66
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 6
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- KVIZTDNKHOCNAM-UHFFFAOYSA-N 4-methylpiperazin-2-one Chemical compound CN1CCNC(=O)C1 KVIZTDNKHOCNAM-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014088094 | 2014-10-03 | ||
| CNPCT/CN2014/088094 | 2014-10-03 | ||
| PCT/US2015/053677 WO2016054483A1 (en) | 2014-10-03 | 2015-10-02 | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019161051A Division JP6794514B2 (ja) | 2014-10-03 | 2019-09-04 | Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530154A JP2017530154A (ja) | 2017-10-12 |
| JP2017530154A5 true JP2017530154A5 (https=) | 2018-11-15 |
| JP6585167B2 JP6585167B2 (ja) | 2019-10-02 |
Family
ID=54330059
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517705A Active JP6585167B2 (ja) | 2014-10-03 | 2015-10-02 | Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 |
| JP2019161051A Active JP6794514B2 (ja) | 2014-10-03 | 2019-09-04 | Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019161051A Active JP6794514B2 (ja) | 2014-10-03 | 2019-09-04 | Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20180185341A1 (https=) |
| EP (1) | EP3200786B1 (https=) |
| JP (2) | JP6585167B2 (https=) |
| ES (1) | ES2756748T3 (https=) |
| PL (1) | PL3200786T3 (https=) |
| WO (1) | WO2016054483A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6585167B2 (ja) * | 2014-10-03 | 2019-10-02 | ノバルティス アーゲー | Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 |
| CN113234072B (zh) * | 2016-05-20 | 2022-11-04 | 江苏豪森药业集团有限公司 | Fgfr4抑制剂、其制备方法和应用 |
| WO2018055503A1 (en) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combination comprising a pd-1 antagonist and an fgfr4 inhibitor |
| SG11201903911UA (en) * | 2016-11-02 | 2019-05-30 | Novartis Ag | Combinations of fgfr4 inhibitors and bile acid sequestrants |
| TWI723480B (zh) * | 2018-07-27 | 2021-04-01 | 大陸商北京加科思新藥研發有限公司 | 用作fgfr4抑制劑的稠環衍生物 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| GB9420999D0 (en) | 1994-10-18 | 1994-12-07 | Smithkline Beecham Plc | Novel compounds |
| CA2261633A1 (en) | 1996-07-29 | 1998-02-05 | Banyu Pharmaceutical Co., Ltd. | Chemokine receptor antagonists |
| US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| AR015514A1 (es) | 1998-02-10 | 2001-05-02 | Novartis Ag | Compuesto de amida, proceso para su preparacion y composicion farmaceutica que lo contiene |
| EP1218336A2 (en) | 1999-09-20 | 2002-07-03 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| CZ20021508A3 (cs) * | 1999-11-08 | 2002-10-16 | Merck & Co., Inc. | Způsob výroby imidazolidinonových derivátů |
| US6407241B1 (en) | 1999-11-08 | 2002-06-18 | Merck & Co., Inc. | Process and intermediates for the preparation of imidazolidinone αv integrin antagonists |
| JPWO2003068753A1 (ja) | 2002-02-14 | 2005-06-02 | 小野薬品工業株式会社 | Ｎ−カルバモイル窒素含有縮合環化合物およびその化合物を有効成分として含有する薬剤 |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US20060004010A1 (en) | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
| WO2004020434A1 (ja) * | 2002-08-30 | 2004-03-11 | Eisai Co., Ltd. | 含窒素芳香環誘導体 |
| AU2003303231A1 (en) | 2002-12-20 | 2004-07-14 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| WO2004080966A1 (ja) | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| EP1613322A4 (en) | 2003-04-11 | 2008-08-13 | Taigen Biotechnology Co Ltd | AMINOQUINOLINE COMPOUNDS |
| US7749999B2 (en) | 2003-09-11 | 2010-07-06 | Itherx Pharmaceuticals, Inc. | Alpha-ketoamides and derivatives thereof |
| CN101223167B (zh) | 2005-07-15 | 2011-08-31 | 弗·哈夫曼-拉罗切有限公司 | 杂芳基稠合的环状胺 |
| WO2007067537A1 (en) * | 2005-12-07 | 2007-06-14 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine kinase inhibiting compounds |
| BRPI0620408B8 (pt) * | 2005-12-21 | 2021-05-25 | Novartis Ag | derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica |
| EP1976528A2 (en) | 2005-12-29 | 2008-10-08 | Janssen Pharmaceutica, N.V. | Prokineticin 2 receptor antagonists |
| EP1989230B1 (en) | 2006-02-10 | 2016-06-01 | Genentech, Inc. | Anti-fgf19 antibodies and methods using same |
| KR20090008217A (ko) | 2006-03-10 | 2009-01-21 | 오노 야꾸힝 고교 가부시키가이샤 | 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제 |
| EP2049490A1 (en) * | 2006-06-09 | 2009-04-22 | Astra Zeneca AB | N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors |
| WO2007146230A2 (en) | 2006-06-14 | 2007-12-21 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
| EP1918376A1 (en) | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| CA2679268A1 (en) | 2007-03-09 | 2008-09-18 | Novartis Ag | Treatment of melanoma |
| SI2550972T1 (en) | 2007-04-02 | 2018-05-31 | Genentech, Inc. | A Klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance |
| WO2009079008A1 (en) | 2007-12-19 | 2009-06-25 | Yangbo Feng | Benzopyrans and analogs as rho kinase inhibitors |
| FR2933702A1 (fr) | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Antagonistes specifiques du recepteur fgf-r4 |
| AU2009289136A1 (en) | 2008-09-03 | 2010-03-11 | Licentia Ltd. | Materials and methods for inhibiting cancer cell invasion related to FGFR4 |
| US20110172217A1 (en) | 2008-09-05 | 2011-07-14 | Shionogi & Co., Ltd. | Ring-fused morpholine derivative having pi3k-inhibiting activity |
| RU2561109C2 (ru) | 2008-12-19 | 2015-08-20 | Дженентек, Инк. | Соединения и способы применения |
| GB0906470D0 (en) * | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| CA2761009A1 (en) | 2009-05-04 | 2010-11-11 | Plexxikon, Inc. | Compounds and methods for inhibition of renin, and indications therefor |
| US9556201B2 (en) | 2009-10-29 | 2017-01-31 | Glaxosmithkline Llc | Bicyclic pyridines and analogs as sirtuin modulators |
| CN102596916B (zh) | 2009-10-30 | 2015-06-17 | 诺瓦提斯公司 | 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲的n-氧化物 |
| KR20120130104A (ko) | 2010-02-01 | 2012-11-28 | 닛뽕 케미파 가부시키가이샤 | Ｇｐｒ119 작동약 |
| WO2011111880A1 (ko) | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| BR112013002112B1 (pt) | 2010-07-29 | 2021-04-06 | Rigel Pharmaceuticals, Inc. | Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição |
| WO2012061337A1 (en) * | 2010-11-02 | 2012-05-10 | Exelixis, Inc. | Fgfr2 modulators |
| JP5620417B2 (ja) * | 2011-02-07 | 2014-11-05 | 中外製薬株式会社 | アミノピラゾール誘導体を含む医薬 |
| AP2013007153A0 (en) | 2011-03-18 | 2013-09-30 | Lupin Ltd | Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators |
| CA2828890A1 (en) | 2011-04-07 | 2012-10-11 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| SMT202100451T1 (it) | 2012-07-11 | 2021-09-14 | Blueprint Medicines Corp | Inibitori del recettore di crescita dei fibroblasti |
| EP2906552B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2014059214A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| US20150290235A1 (en) | 2012-11-23 | 2015-10-15 | Ab Science | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| EP3019491A4 (en) | 2013-07-09 | 2016-12-21 | Dana Farber Cancer Inst Inc | KINASEHEMMER FOR THE TREATMENT OF DISEASES |
| AR097455A1 (es) | 2013-08-28 | 2016-03-16 | Astellas Pharma Inc | Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo |
| MX378288B (es) | 2013-10-18 | 2025-03-10 | Eisai R&D Man Co Ltd | Inhibidores de pirimidina del fgfr4. |
| CA2928042C (en) | 2013-10-25 | 2022-05-10 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| CN105683188B (zh) * | 2013-10-25 | 2018-02-09 | 诺华股份有限公司 | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| JP6585167B2 (ja) * | 2014-10-03 | 2019-10-02 | ノバルティス アーゲー | Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 |
| US9802917B2 (en) * | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| EP3273959A1 (en) * | 2015-03-25 | 2018-01-31 | Novartis Ag | Pharmaceutical combinations |
| SG11201903911UA (en) | 2016-11-02 | 2019-05-30 | Novartis Ag | Combinations of fgfr4 inhibitors and bile acid sequestrants |
-
2015
- 2015-10-02 JP JP2017517705A patent/JP6585167B2/ja active Active
- 2015-10-02 US US15/516,443 patent/US20180185341A1/en not_active Abandoned
- 2015-10-02 WO PCT/US2015/053677 patent/WO2016054483A1/en not_active Ceased
- 2015-10-02 PL PL15781518T patent/PL3200786T3/pl unknown
- 2015-10-02 ES ES15781518T patent/ES2756748T3/es active Active
- 2015-10-02 EP EP15781518.4A patent/EP3200786B1/en active Active
-
2018
- 2018-11-13 US US16/190,087 patent/US10463653B2/en active Active
-
2019
- 2019-02-28 US US16/289,612 patent/US10507201B2/en active Active
- 2019-09-04 JP JP2019161051A patent/JP6794514B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530154A5 (https=) | ||
| JP6823095B2 (ja) | 噴霧乾燥製剤 | |
| JP6664385B2 (ja) | Ｂｕｂ１阻害薬としてのベンジル置換インダゾール類 | |
| RU2686323C2 (ru) | Новые соединения и композиции для ингибирования fasn | |
| JP7215687B2 (ja) | キナーゼ阻害活性を有する化合物、その製造方法及び用途 | |
| JP6952695B2 (ja) | インフルエンザウイルス複製の阻害剤、その適用方法および使用 | |
| JP6387488B2 (ja) | 非選択的キナーゼ阻害剤 | |
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| JP2010528026A5 (https=) | ||
| RU2013109143A (ru) | Бензимидазол- и азабензимидазолсодержащие соединения, которые ингибируют киназу анапластической лимфомы | |
| CN107922431A (zh) | Hpk1抑制剂及其使用方法 | |
| JP2014513110A5 (https=) | ||
| AU2014337154A1 (en) | Co-crystals of (s)-N-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as DNA-PK inhibitors | |
| WO2015058067A1 (en) | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors | |
| KR20110036620A (ko) | Ｓｍｏ 억제제로서의 피리다진 유도체 | |
| JP2016525076A5 (https=) | ||
| CN105308036A (zh) | 用于激酶调节的化合物和方法及其适应症 | |
| TW201028393A (en) | Kinase inhibitors and methods of their use | |
| RU2014154009A (ru) | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания | |
| JP2017527586A (ja) | 癌の治療に有用な縮合二環式（ヘテロ）芳香族化合物 | |
| JP2013173787A (ja) | 薬剤耐性癌の処置方法 | |
| WO2014187922A1 (en) | Slc2a transporter inhibitors | |
| JP2017536342A5 (https=) | ||
| CN105777653A (zh) | 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物 | |
| RU2015101702A (ru) | Фармацевтически активные соединения |